SCHEMBL508430

SCHEMBL508430

c1c[nH]c(Cc2ccc3[nH]ccc3c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 6/20 0.53
CYP17A1 P05093 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
AHR P35869 3/20 0.41
NR4A2 P43354 2/20 0.41
CYP2A6 P11509 2/20 0.41
F7 P08709 1/20 0.41
LTA4H P09960 1/20 0.41
F3 P13726 1/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
RAD51 Q06609 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTR1A P08908 1/20 0.40
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27582729 0.79 TAAR1 (0.64) TAAR1ADRA2AADRA2BADRA2CCYP2A6
SCHEMBL13372830 0.78 TAAR1 (0.80) TAAR1ADRA2AADRA2BADRA2CALOX15
SCHEMBL10679401 0.77 TAAR1 (0.53) TAAR1ADRA2AADRA2BADRA2CALOX15
SCHEMBL31414967 0.75 TAAR1 (0.75) TAAR1ADRA2AADRA2BADRA2CGAA
SCHEMBL11295655 0.75 TAAR1 (0.58) TAAR1ADRA2AADRA2BADRA2CGAA
SCHEMBL19033361 0.74 TAAR1 (0.49) TAAR1GAAALOX15HTR1A
SCHEMBL10697156 0.73 TAAR1 (0.56) TAAR1CYP17A1CYP11B1CYP11B2ADRA2A
SCHEMBL8666600 0.73 HDAC1 (0.55) CYP17A1CYP11B1CYP11B2AHRNR4A2
SCHEMBL30030142 0.73 CYP17A1 (0.55) CYP17A1CYP11B1CYP11B2AHRNR4A2
SCHEMBL8604113 0.73 CYP17A1 (0.55) CYP17A1CYP11B1CYP11B2AHRNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028940-A1 FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2012-02-02 US disclosed
EP-2344491-A2 FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS Schering Corporation (US) 2011-07-20 EP disclosed
WO-2010042477-A1 BENZODIOXAN ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS SCHERING CORPORATION (US) 2010-04-15 WO disclosed
WO-2010033495-A2 FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028940-A1 FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS ADRA2C, ADRB2, ADRA2A TAAR1 51/4885CYP17A1 1716/4885CYP11B1 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.